Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

Stocks of cancer treatment developers will be moving into the spotlight later this week when the annual meeting of the ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Introduction Oncology drugs are medications used to prevent or treat cancer. These include chemotherapy, targeted therapy, immunotherapy, and h ...

Almost six years on, we're one of the fastest growing oncology companies in the world. We continue to drive forward with this approach supporting patients with cancer in the UK, and around the world.

Accordingly, investing in AI-driven precision oncology companies presents a compelling long-term opportunity for investors. BioXcel: The company expedites the discovery and development of new ...